IJR News — today's news from every side

IJR News — today's news from every side

blockversewordysbillionaire.aiyourlistWhiteboardAppquizieunschool

Loading

Want your own hosted, self-optimizing clone of this — or any OpenServe site? Open Development for enterprise →

© OpenServe Holdings LLC

Privacy Notice Data rights Terms of Service Feedback Cookie NoticeHelp Acceptable Use Copyright AI Notice Your Privacy Choices Subprocessors Data Processing Addendum Installed App Terms Company Solutions Free assessment Investors Get the app Contact

News

Home
Politics
World
Sports
Markets
Business
Entertainment
Music
Health
Tech
Science
Good News
Encouragement
Video
Meme Wars

Brands

Yourlist
Quizie
FaithTap
Blessed
All brands

Cipla and Qilu ink exclusive deal to sell Keytruda biosimilar in US — Sep 3, 2026Invagen Pharmaceuticals has signed an exclusive US licensing deal with Qilu Pharmaceutical to commercialize QL2107, a Keytruda (pembrolizumab) biosimilar, with Qilu handling development, regulatory work, and supply while Cipla USA drives commercialization. The arrangement underscores Cipla’s strategy to expand its oncology-focused biosimilars portfolio and reduce cancer treatment costs for patients, following multiple collaborations with Chinese manufacturers.

Derek Foss Patent cliff for Keytruda can't come soon enough. Hope this actually translates to lower prices once it hits the US market, not just corporate profit shifting.

Q1 Earnings Season Kicks Off Across India — Jul 23, 2026Indian markets brace for a high-volume Q1 FY27 earnings day on July 23, with about 60 companies including Infosys, IndiGo, Cipla, Meesho, PVR Inox and others reporting, as investors weigh AI spending, travel demand, margins, and fuel costs. Analysts anticipate Infosys to show modest revenue growth with margin gains and IndiGo to lift yields despite fuel-cost headwinds, signaling a pivotal moment for guidance across IT, aviation, and consumer sectors.

Trump tariffs hit Indian pharma stocks — Jul 22, 2026Indian pharmaceutical stocks slid after US President Donald Trump unveiled a phased tariff plan for imported generic medicines, offering a two-year zero-tariff window beginning August 1, 2026, followed by 100% tariffs from August 2028 and 200% from August 2029, fueling concerns about US-facing revenue for Indian drugmakers. The move dragged the Nifty Pharma index and major exporters like Sun Pharma, Cipla and Dr Reddy’s lower as investors reassess long-term earnings amid the policy shift.